ATRC News and Press, AtriCure Inc. From 10/29/25

2025-10-29 23:17:17 ET More on AtriCure AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for AtriCure Financial information for AtriCure Read the full article on Seeking ...

2025-10-29 23:16:23 ET AtriCure, Inc. (ATRC) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer ... Read the full article on Seeking Alpha For f...

2025-10-29 16:05:12 ET More on AtriCure Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for AtriCure Financial information for AtriCure Read the full article on Seeking Alpha For further details see: AtriCure Non-GAAP EPS ...

Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year Generated $30...

Amerigo Resources Ltd (ARREF) is expected to report $0.06 for Q3 2025 Bausch + Lomb Corporation (BLCO) is expected to report $0.16 for Q3 2025 Hayward Holdings Inc. (HAYW) is expected to report $0.11 for Q3 2025 Automatic Data Processing Inc. (ADP) is expected to report $2.44 for Q1 2...

Trial will evaluate the safety and effectiveness of the AtriCure Isolator ® Synergy™ EnCompass ® clamp and AtriClip ® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset atrial fibrillation in cardiac surgery patients AtriCu...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in upcoming investor conferences. ...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2025 financial results on Wednesday, O...

New device expands AtriCure’s market opportunity in post-operative pain management while addressing a significant unmet clinical need AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial ap...

2025-07-29 19:14:40 ET More on AtriCure AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript AtriCure: Profits And Operating Leverage Are Needed Here Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for AtriCure Financial inf...